DK1864981T3 - Thrombopoietin-mimetiske stoffer - Google Patents

Thrombopoietin-mimetiske stoffer

Info

Publication number
DK1864981T3
DK1864981T3 DK07112105T DK07112105T DK1864981T3 DK 1864981 T3 DK1864981 T3 DK 1864981T3 DK 07112105 T DK07112105 T DK 07112105T DK 07112105 T DK07112105 T DK 07112105T DK 1864981 T3 DK1864981 T3 DK 1864981T3
Authority
DK
Denmark
Prior art keywords
thrombopoietin mimetic
mimetic substances
substances
thrombopoietin
mimetic
Prior art date
Application number
DK07112105T
Other languages
Danish (da)
English (en)
Inventor
Kevin J Duffy
Daniel F Eppley
Connie L Erickson-Miller
Julian Jenkins
Nannan Liu
Juan I Luengo
Alan T Price
Antony N Shaw
Sophie Visonneau
Kenneth Wiggall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1864981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1864981T3 publication Critical patent/DK1864981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hard Magnetic Materials (AREA)
  • Information Transfer Systems (AREA)
  • Vehicle Body Suspensions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK07112105T 2000-05-25 2001-05-24 Thrombopoietin-mimetiske stoffer DK1864981T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20708400P 2000-05-25 2000-05-25
US22892900P 2000-08-30 2000-08-30
PCT/US2001/016863 WO2001089457A2 (en) 2000-05-25 2001-05-24 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
DK1864981T3 true DK1864981T3 (da) 2009-09-07

Family

ID=26901947

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07112106.5T DK1889838T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetika
DK01941599T DK1294378T3 (da) 2000-05-25 2001-05-24 Trombopoietin-mimetika
DK07112105T DK1864981T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetiske stoffer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK07112106.5T DK1889838T3 (da) 2000-05-25 2001-05-24 Thrombopoietin-mimetika
DK01941599T DK1294378T3 (da) 2000-05-25 2001-05-24 Trombopoietin-mimetika

Country Status (30)

Country Link
US (9) US7160870B2 (OSRAM)
EP (3) EP1864981B8 (OSRAM)
JP (2) JP3813875B2 (OSRAM)
KR (2) KR100847172B1 (OSRAM)
CN (4) CN101343251B (OSRAM)
AR (2) AR030696A1 (OSRAM)
AT (2) ATE445606T1 (OSRAM)
AU (2) AU7493801A (OSRAM)
BE (1) BE2010C018I2 (OSRAM)
BR (1) BRPI0111116B8 (OSRAM)
CA (1) CA2411468C (OSRAM)
CY (4) CY2010012I2 (OSRAM)
CZ (1) CZ303176B6 (OSRAM)
DE (4) DE122010000037I1 (OSRAM)
DK (3) DK1889838T3 (OSRAM)
ES (3) ES2294000T3 (OSRAM)
FR (1) FR10C0034I2 (OSRAM)
HK (1) HK1056114A1 (OSRAM)
HU (3) HU230387B1 (OSRAM)
IL (5) IL152988A0 (OSRAM)
LU (1) LU91681I2 (OSRAM)
MX (1) MXPA02011621A (OSRAM)
MY (1) MY136707A (OSRAM)
NO (3) NO324246B1 (OSRAM)
NZ (2) NZ533308A (OSRAM)
PL (2) PL218617B1 (OSRAM)
PT (3) PT1864981E (OSRAM)
SI (3) SI1294378T1 (OSRAM)
TW (1) TWI305207B (OSRAM)
WO (1) WO2001089457A2 (OSRAM)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245532B2 (en) * 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2002085343A1 (en) * 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja) * 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチン疑似体
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
EP2387998A1 (en) * 2003-04-29 2011-11-23 Glaxosmithkline LLC Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US7753958B2 (en) * 2003-08-05 2010-07-13 Gordon Charles R Expandable intervertebral implant
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006034474A2 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
EP1805155B1 (en) 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
EP1819692A1 (en) 2004-12-08 2007-08-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
EP1845090A4 (en) 2004-12-14 2009-11-11 Nissan Chemical Ind Ltd AMIDE COMPOUND AND THROMBOPOIETINE RECEPTOR ACTIVATOR
TW200716580A (en) 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
US7968542B2 (en) 2005-07-15 2011-06-28 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
JP5104752B2 (ja) 2005-07-20 2012-12-19 日産化学工業株式会社 ピラゾール化合物及びトロンボポエチンレセプター活性化剤
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
WO2008070583A2 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
JP2010525072A (ja) * 2007-04-24 2010-07-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｔｐｏ模倣薬としてのヒドロキシ−１−アゾ−誘導体の新規な製造方法
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
BRPI0818346A2 (pt) 2007-10-09 2015-04-07 Univ Pennsylvania Morte de células de leucemia mielóide aguda humana pelo agonista de receptor de trombopoietina(tpora)
CN101481352A (zh) * 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (en) * 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
EP2348858A4 (en) * 2008-10-16 2013-06-12 Glaxosmithkline Llc PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
TWI379681B (en) * 2009-04-01 2012-12-21 Pliva Hrvatska D O O Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
JP2012526137A (ja) * 2009-05-07 2012-10-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血小板減少症を治療する方法
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
SI3127427T1 (sl) * 2009-05-29 2020-07-31 Novartis Ag Postopki dajanja spojin agonista trombopoetina
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
JP5684827B2 (ja) 2009-12-01 2015-03-18 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリウレタン−ベースのプルトルージョン樹脂系
CN101805291A (zh) * 2010-04-26 2010-08-18 西北大学 1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
BR112013004714A2 (pt) 2010-09-01 2016-05-17 Novartis Ag "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2012121957A1 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2013006806A1 (en) * 2011-07-06 2013-01-10 Cellerant Therapeutics, Inc. Megakaryocyte progenitor cells for production of platelets
PH12014500371A1 (en) * 2011-08-30 2021-06-02 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755955A4 (en) 2011-09-13 2015-08-19 Glenmark Generics Ltd METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
WO2013049605A1 (en) 2011-09-28 2013-04-04 Assia Chemical Industries Ltd. Processes for the preparation of an intermediate in the synthesis of eltrombopag
AU2012322660B2 (en) 2011-10-11 2017-07-06 Dana Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic BAX
US9492430B2 (en) 2011-11-14 2016-11-15 Ligand Pharmaceuticals, Incorporated Methods and compositions associated with the granulocyte colony-stimulating factor receptor
HK1203081A1 (en) 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2807165B1 (en) 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014150252A1 (en) 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (en) 2013-04-29 2014-11-05 Esteve Química, S.A. Preparation process of an agonist of the thrombopoietin receptor
EP3041511B1 (en) 2013-09-02 2021-06-02 Hetero Research Foundation Compositions of eltrombopag
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种爱曲伯帕的合成方法
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (zh) * 2014-03-17 2015-04-08 苏州明锐医药科技有限公司 艾曲波帕的制备方法
CN106414445B (zh) 2014-04-22 2020-07-03 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
CN105085287A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
CN105085276A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 艾曲波帕中间体及其制备方法和应用
PE20170770A1 (es) 2014-07-17 2017-07-04 Chdi Foundation Inc Metodos y composiciones para tratar trastornos relacionados con vih
US10336706B2 (en) 2014-09-05 2019-07-02 Hetero Research Foundation Crystalline form of Eltrombopag free acid
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
US10724028B2 (en) 2014-10-31 2020-07-28 Nissan Chemical Industries, Ltd. Ligand-binding fiber and cell culture substrate using said fiber
CN104829593B (zh) * 2015-03-26 2017-08-25 苏州福来兹检测科技有限公司 一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
CA3021103A1 (en) 2016-04-21 2017-10-26 Basf Se Method for producing pultruded products on the basis of polyurethane
EP3474834B1 (en) 2016-06-27 2025-04-09 The General Hospital Corporation Dba Massachusetts General Hospital Stimulating platelet formation with bezafibrate, resveratrol or srt1720 to treat thrombocytopenia
KR20190123332A (ko) 2017-03-09 2019-10-31 바스프 에스이 복합 요소의 제조를 위한 폴리우레탄 제제
CN107021928B (zh) * 2017-04-01 2022-11-18 常州制药厂有限公司 艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
EP3692021A1 (en) 2017-10-06 2020-08-12 Assia Chemical Industries Ltd Solid state forms of eltrombopag choline
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN110467531B (zh) * 2018-05-09 2022-04-19 新发药业有限公司 一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
WO2019229572A1 (en) * 2018-06-01 2019-12-05 Aurobindo Pharma Ltd An improved process for the preparation of eltrombopag olamine and its intermediates
EP3604284B1 (en) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline eltrombopag monoethanolamine salt form d
ES2815924T3 (es) 2018-08-02 2021-03-31 Fis Fabbrica Italiana Sintetici Spa Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
TW202042806A (zh) * 2019-01-08 2020-12-01 大陸商江蘇恒瑞醫藥股份有限公司 雙環取代吡唑酮偶氮類衍生物的給藥方案
CA3143873C (en) 2019-07-04 2023-09-19 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
WO2021055820A1 (en) 2019-09-20 2021-03-25 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN114341112A (zh) * 2019-10-21 2022-04-12 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
CN114341113A (zh) * 2019-10-21 2022-04-12 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
CA3160779A1 (en) 2019-12-06 2021-06-10 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
EP4069203A1 (en) 2019-12-06 2022-10-12 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (en) 2021-03-25 2022-09-29 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (zh) * 2021-06-11 2022-10-11 上海大学 丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) * 2021-12-02 2022-05-17 天津力生制药股份有限公司 一种艾曲波帕的制备方法
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag
CN116354885A (zh) * 2021-12-27 2023-06-30 苏州特瑞药业股份有限公司 一种艾曲波帕新晶型及其制备方法
WO2025140275A1 (zh) * 2023-12-25 2025-07-03 江苏恒瑞医药股份有限公司 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (OSRAM)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) * 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) * 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
EP0661170B1 (en) * 1993-12-28 1998-09-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021920A1 (en) 1994-02-14 1995-08-17 Zymogenetics, Inc. Hematopoietic protein and materials and methods for making it
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
CA2223449C (en) 1995-06-07 2008-10-07 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU738473B2 (en) * 1997-10-31 2001-09-20 Glaxosmithkline Llc Novel metal complexes
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
EP1207155A4 (en) 1999-07-26 2005-01-12 Shionogi & Co DRUG COMPOSITIONS HAVING AGONIST THROMBOPOIETINE ACTIVITY
ATE315934T1 (de) * 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
WO2001021180A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AR030273A1 (es) 2000-03-10 2003-08-20 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6642265B1 (en) * 2000-09-08 2003-11-04 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002239718A1 (en) 2000-12-19 2002-07-01 Ligand Pharmaceuticals Thrombopoietin mimetics
EP1351979B1 (en) 2000-12-21 2008-01-16 Smithkline Beecham Corporation Regulated activation of cell-membrane receptors by metal-chelating agonists
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
KR20040025891A (ko) 2001-01-26 2004-03-26 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 효현작용을 갖는 할로겐 화합물
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
US6560161B1 (en) * 2001-08-30 2003-05-06 Micron Technology, Inc. Synchronous flash memory command sequence
MXPA04005204A (es) 2001-11-30 2005-11-04 Quadra Logic Tech Inc Derivados de hidrazonipirazol y su uso como terpapeuticos.
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja) * 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチン疑似体
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
WO2004054515A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
EP2387998A1 (en) * 2003-04-29 2011-11-23 Glaxosmithkline LLC Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
EP1805155B1 (en) * 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage
WO2008070583A2 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics

Also Published As

Publication number Publication date
US20070129338A1 (en) 2007-06-07
US20090176746A1 (en) 2009-07-09
MXPA02011621A (es) 2004-05-17
SI1294378T1 (sl) 2008-02-29
CN1444477A (zh) 2003-09-24
US7452874B2 (en) 2008-11-18
DE60130760T2 (de) 2008-07-17
US7335649B2 (en) 2008-02-26
CY2010012I1 (el) 2012-01-25
IL152988A (en) 2009-02-11
HK1055561A1 (en) 2004-01-16
NO324246B1 (no) 2007-09-17
US7674887B2 (en) 2010-03-09
TWI305207B (en) 2009-01-11
BR0111116B1 (pt) 2013-10-08
WO2001089457A3 (en) 2002-03-07
HK1056114A1 (zh) 2004-02-06
AU2001274938C1 (en) 2006-09-28
KR20070087255A (ko) 2007-08-27
US20090155203A1 (en) 2009-06-18
IL152988A0 (en) 2003-06-24
EP1864981B1 (en) 2009-07-22
FR10C0034I1 (OSRAM) 2010-06-08
CA2411468C (en) 2008-04-15
HU230487B1 (hu) 2016-08-29
NO2010017I2 (no) 2012-06-11
PT1294378E (pt) 2008-01-09
EP1889838B1 (en) 2009-10-14
US20080090787A1 (en) 2008-04-17
US7160870B2 (en) 2007-01-09
PT1864981E (pt) 2009-08-31
NO20025566L (no) 2003-01-22
US7332481B2 (en) 2008-02-19
CA2411468A1 (en) 2001-11-29
NZ533308A (en) 2005-10-28
JP4546919B2 (ja) 2010-09-22
PL359270A1 (en) 2004-08-23
AU7493801A (en) 2001-12-03
US20090176973A1 (en) 2009-07-09
IL193617A0 (en) 2009-02-11
KR100847172B1 (ko) 2008-07-17
ES2294000T3 (es) 2008-04-01
HU230387B1 (hu) 2016-03-29
LU91681I9 (OSRAM) 2019-01-03
US7473686B2 (en) 2009-01-06
BRPI0111116B8 (pt) 2021-05-25
KR100798568B1 (ko) 2008-01-28
ES2334843T3 (es) 2010-03-16
CY1107087T1 (el) 2012-01-25
EP1294378A2 (en) 2003-03-26
HK1113057A1 (en) 2008-09-19
WO2001089457A2 (en) 2001-11-29
US20080090996A1 (en) 2008-04-17
EP1294378A4 (en) 2004-01-28
PL218617B1 (pl) 2015-01-30
LU91681I2 (fr) 2010-06-21
SI1889838T1 (sl) 2010-02-26
JP2006137764A (ja) 2006-06-01
HU0800310D0 (en) 2008-07-28
CN101343250B (zh) 2011-09-21
MY136707A (en) 2008-11-28
PL393259A1 (pl) 2011-07-04
CY1109730T1 (el) 2014-09-10
EP1864981B8 (en) 2009-11-11
BR0111116A (pt) 2003-04-08
IL193618A0 (en) 2009-02-11
CY1109435T1 (el) 2014-08-13
CZ20023852A3 (cs) 2003-05-14
DE60139354D1 (de) 2009-09-03
FR10C0034I2 (fr) 2011-04-29
US20080214640A1 (en) 2008-09-04
IL193617A (en) 2013-06-27
JP2003534257A (ja) 2003-11-18
CN101343251A (zh) 2009-01-14
DE122010000037I1 (de) 2011-01-27
NO2010017I1 (no) 2010-09-20
US7648971B2 (en) 2010-01-19
HUP0800710A2 (hu) 2003-10-28
NZ522474A (en) 2004-10-29
PL216528B1 (pl) 2014-04-30
ES2328179T3 (es) 2009-11-10
AU2001274938B2 (en) 2006-01-19
EP1889838A1 (en) 2008-02-20
EP1294378B1 (en) 2007-10-03
DK1294378T3 (da) 2008-01-28
CY2010012I2 (el) 2020-05-29
HK1117825A1 (en) 2009-01-23
CZ303176B6 (cs) 2012-05-16
IL193619A0 (en) 2009-02-11
CN101343250A (zh) 2009-01-14
ATE445606T1 (de) 2009-10-15
CN101342169A (zh) 2009-01-14
US20070179192A1 (en) 2007-08-02
US7439342B2 (en) 2008-10-21
US20040019190A1 (en) 2004-01-29
DE60130760D1 (de) 2007-11-15
NO20025566D0 (no) 2002-11-20
PT1889838E (pt) 2010-01-19
DK1889838T3 (da) 2010-02-08
HU0800710D0 (en) 2009-01-28
EP1864981A1 (en) 2007-12-12
JP3813875B2 (ja) 2006-08-23
ATE374772T1 (de) 2007-10-15
HUP0302257A3 (en) 2007-03-28
SI1864981T1 (sl) 2009-12-31
NO2020040I1 (no) 2020-11-19
AR066036A2 (es) 2009-07-22
AR030696A1 (es) 2003-09-03
CN100423721C (zh) 2008-10-08
BE2010C018I2 (OSRAM) 2020-08-20
CN101343251B (zh) 2011-11-09
HUP0302257A2 (hu) 2003-10-28
KR20030060773A (ko) 2003-07-16
US7790704B2 (en) 2010-09-07
HU227476B1 (en) 2011-07-28
DE60140224D1 (de) 2009-11-26

Similar Documents

Publication Publication Date Title
DK1864981T3 (da) Thrombopoietin-mimetiske stoffer
DE50105915D1 (de) Schutzhülle
NL1017075A1 (nl) Preparaat.
MX242679B (es) Antranilamidas insecticidas.
ATE300177T1 (de) Pestizide zusammensetzung
DE60102994D1 (de) Fritiergerät
FI20000004A0 (fi) Flavonoidilääke...
ID29326A (id) Popok sekali pakai
ID28863A (id) Popok sekali pakai
NO20030917D0 (no) Anvendelse
DE60125415D1 (de) Formeinsatz
DE60106821D1 (de) Fritiergerät
DE60105231D1 (de) Fritiergerät
CH695519A5 (de) Sperrstromthyristor.
DE60132814D1 (de) Te
DE60100532D1 (de) Fritiergerät
DE60100772D1 (de) Fritiergerät
FR2815239B1 (fr) Barbecue
ES1045827Y (es) Jamonero
ES1047136Y (es) Antirrobo para motocicletas.
ES1046518Y (es) Disposicion de bandera y similares.
SE0002606D0 (sv) Watcher
NO20002762D0 (no) Grill
LT2000061A (lt) Pyrago gaminys su karotinu
FI20001849A0 (fi) Laude